pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN
SUPERNUS PHARMACEUTICALS
SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 9715 Key West Ave, Rockville, Maryland 20850, US
- Founded
- 2005
- Employees
- 828
- Programs
- 55
- Drugs
- 25
- Patents
- 68
SUPERNUS PHARMACEUTICALS projects
8 ClinicalTrials.gov programs sponsored by SUPERNUS PHARMACEUTICALS.
SUPERNUS PHARMACEUTICALS has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BIS-001 ER
SUPERNUS PHARMACEUTICALS, INC.
Epilepsy, Complex Partial
1 trial -
SAGE-718
SUPERNUS PHARMACEUTICALS, INC.
Healthy Volunteer
3 trials -
SAGE-904
SUPERNUS PHARMACEUTICALS, INC.
Healthy Volunteer
1 trial -
SPN-804O
SUPERNUS PHARMACEUTICALS, INC.
Epilepsies, Partial
1 trial -
SPN-810M
SUPERNUS PHARMACEUTICALS, INC.
Impulsive Aggression Comorbid With ADHD
1 trial -
SPN-817, Treatment B
SUPERNUS PHARMACEUTICALS, INC.
Healthy Volunteer
1 trial -
Topiramate IR
SUPERNUS PHARMACEUTICALS, INC.
Epilepsy
1 trial -
[14C]-NV-5138
SUPERNUS PHARMACEUTICALS, INC.
Healthy Volunteers
2 trials
Frequently asked questions
How many clinical projects does SUPERNUS PHARMACEUTICALS have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.